Aro Biotherapeutics

Aro Biotherapeutics | Targeted Genetic Medicine | United States

Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary ...

Aro Biotherapeutics Secures $41.5M Series B Financing

Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced it has secured $41 ...

Aro Biotherapeutics - LinkedIn

Aro Biotherapeutics | 4879 followers on LinkedIn. | Unlocking the Potential of Genetic Medicines Based in Philadelphia, Aro Biotherapeutics ...

Aro Biotherapeutics Company | Life Sciences PA

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a ...

Invest In Aro Biotherapeutics Stock | Buy Pre-IPO Shares | EquityZen

Join now and verify your accreditation status to gain access to: · Aro Biotherapeutics current valuation · Aro Biotherapeutics stock price · Available deals in ...

Aro Biotherapeutics - BioSpace

Aro Biotherapeutics · Press Releases · Aro Biotherapeutics Opens Enrollment of Phase 1b Trial of ABX1100 in Patients with Late-Onset Pompe Disease (LOPD).

Aro Biotherapeutics - Crunchbase Company Profile & Funding

Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.

Aro Biotherapeutics Announces $88 Million Series A Financing to ...

Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the closing of ...

Aro Biotherapeutics Company Profile 2024 - PitchBook

Developer of a protein drug platform designed to unlock the potential of genetic medicines. The company's drugs are small, non-antibody protein scaffolds.

Aro Biotherapeutics company information, funding & investors

Aro Biotherapeutics, focused on the development of a new protein drug platform. Here you'll find information about their funding, investors and team.

Aro Biotherapeutics raises funds for Pompe disease therapy

Aro Biotherapeutics has raised $41.5m in a Series B financing round to advance the development of ABX1100 for Pompe disease.

Aro Biotherapeutics Careers, Perks + Culture | Built In

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines.

Aro Biotherapeutics to Present New Preclinical Data Highlighting the ...

Results of recent studies demonstrate that Aro's muscle-targeted Centyrin-siRNA conjugate robustly reduces toxic accumulation of muscle glycogen in a murine ...

Aro Biotherapeutics Stock Price, Funding, Valuation ... - CB Insights

See Aro Biotherapeutics funding rounds, investors, investments, exits and more. Evaluate their financials based on Aro Biotherapeutics's post-money ...

Aro Biotherapeutics Secures $41.5M Series B Financing

PHILADELPHIA, November 28, 2023--Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted ...

Aro Biotherapeutics | Institution outputs | Nature Index

Research. Date range: 1 September 2023 - 31 August 2024. No articles found. Aro Biotherapeutics did not contribute to any primary ...

Aro Biotherapeutics Co. - Drug pipelines, Patents, Clinical trials

ABX9xx is a bispecific Centyrin targeting the Met-EGFR axis, an emerging cancer treatment paradigm. Centyrins are small, chemically simple proteins.

Aro Biotherapeutics - BIO International Convention 2024

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Aro Biotherapeutics Secures $41.5M in Series B Funding to ...

Aro Biotherapeutics announces a significant $41.5M Series B funding round led by Cowen Healthcare Investments, with participation from ...

Aro Biotherapeutics Announces Start of First in Human Study with ...

PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted ...

Aro Biotherapeutics

Aro Biotherapeutics Company

Bruce A. Peacock

RNAi-Based Therapeutics Summit